122| Parkinson’s Disease – With Dr. Sara Schaefer

This episode is a wide ranging discussion of Parkinson’s disease, with Sara Schaefer, MD, MHS. The conversation begins with basic facts, features, and concepts, and then moves into more complex topics, while covering many critical factors for neuropsychologists to consider. It includes a focus on diagnosis/symptoms, epidemiology, core neuropathology, neurodiagnostic approaches, risk factors (e.g., REM behavior disorder), nonmotor features (e.g., autonomic, neuropsychiatric, cognitive), subtypes, and treatment approaches.

If you’d like to receive APA-approved CE credit for listening to this episode, click here.

About Sara

Dr. Schaefer is a graduate of Brown University and The Ohio State University College of Medicine, and an alumna of the Yale Neurology Residency Program. She completed 2 years of subspecialty training in movement disorders at Yale. She has a particular interest in medical education, and completed a Masters of Health Sciences with a focus on medical education in 2019. She has designed an interactive, video-based online training curriculum in movement disorders for residents and medical students that is used by learners all over the world. She serves as co-founder and deputy editor of the MDS podcast, launched January 2019, founder and producer of Neurology Nuts and Bolts: Constructing your Career podcast, launched February 2022, serves as the Movement Disorders Section Head of the Annual Academy of Neurology Resident In-Service Training Examination (RITE) Committee, and as the CME editor for the Movement Disorders Journal.

Selected Resources

JAMA article on Muhammad Ali


Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017). Cognitive decline in parkinson disease. Nature Reviews Neurology, 13(4), 217–231. https://doi.org/10.1038/nrneurol.2017.27

Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2011). Depression in parkinson disease—epidemiology, mechanisms and management. Nature Reviews Neurology, 8(1), 35–47. https://doi.org/10.1038/nrneurol.2011.189

Anang, J. B. M., Postuma, R. B., Gagnon, J.-F., Bertrand, J.-A., Romenets, S. R., Latreille, V., Panisset, M., & Montplaisir, J. (2014). Predictors of dementia in parkinson disease: A prospective cohort study. Neurology, 83, 1253–1260.

Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of parkinson disease. JAMA, 323(6), 548. https://doi.org/10.1001/jama.2019.22360

Berg, D., Adler, C. H., Bloem, B. R., Chan, P., Gasser, T., Goetz, C. G., Halliday, G., Lang, A. E., Lewis, S., Li, Y., Liepelt-Scarfone, I., Litvan, I., Marek, K., Maetzler, C., Mi, T., Obeso, J., Oertel, W., Olanow, C. W., Poewe, W., … Postuma, R. B. (2018). Movement disorder society criteria for clinically established early parkinson’s disease. Movement Disorders, 33(10), 1643–1646. https://doi.org/10.1002/mds.27431

Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., Lang, A. E., Liepelt-Scarfone, I., Litvan, I., Marek, K., Obeso, J., Oertel, W., Olanow, C. W., Poewe, W., Stern, M., & Deuschl, G. (2015). MDS research criteria for Prodromal Parkinson’s disease. Movement Disorders, 30(12), 1600–1611. https://doi.org/10.1002/mds.26431

Caspell-Garcia, C., Simuni, T., Tosun-Turgut, D., Wu, I.-W., Zhang, Y., Nalls, M., Singleton, A., Shaw, L. A., Kang, J.-H., Trojanowski, J. Q., Siderowf, A., Coffey, C., Lasch, S., Aarsland, D., Burn, D., Chahine, L. M., Espay, A. J., Foster, E. D., Hawkins, K. A., … Weintraub, D. (2017). Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo parkinson disease. PLOS ONE, 12(5). https://doi.org/10.1371/journal.pone.0175674

Chahine, L. M., Urbe, L., Caspell-Garcia, C., Aarsland, D., Alcalay, R., Barone, P., Burn, D., Espay, A. J., Hamilton, J. L., Hawkins, K. A., Lasch, S., Leverenz, J. B., Litvan, I., Richard, I., Siderowf, A., Coffey, C. S., Simuni, T., & Weintraub, D. (2018). Cognition among individuals along a spectrum of increased risk for parkinson’s disease. PLOS ONE, 13(8). https://doi.org/10.1371/journal.pone.0201964

Connolly, B. S., & Lang, A. E. (2014). Pharmacological treatment of parkinson disease. JAMA, 311(16), 1670. https://doi.org/10.1001/jama.2014.3654

Deng, H., Wang, P., & Jankovic, J. (2018). The genetics of parkinson disease. Ageing Research Reviews, 42, 72–85. https://doi.org/10.1016/j.arr.2017.12.007

Dorsey, E. R., & Bloem, B. R. (2018). The parkinson pandemic—a call to action. JAMA Neurology, 75(1), 9. https://doi.org/10.1001/jamaneurol.2017.3299

Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the parkinson pandemic. Journal of Parkinson’s Disease, 8(s1). https://doi.org/10.3233/jpd-181474

Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., Greenamyre, J. T., Cambi, F., Yamasaki, T. R., Tanner, C. M., Gan-Or, Z., Litvan, I., Mata, I. F., Zabetian, C. P., Brundin, P., … Leverenz, J. B. (2019). Revisiting protein aggregation as pathogenic in sporadic parkinson and alzheimer diseases. Neurology, 92(7), 329–337. https://doi.org/10.1212/wnl.0000000000006926

Gasca‐Salas, C., Duff‐Canning, S., Armstrong, M. J., Eslinger, P. J., Schneider, R. B., Kennedy, N., Chou, K. L., Persad, C., Litvan, I., Weintraub, S., & Marras, C. (2020). Parkinson disease with mild cognitive impairment: Domain‐specific cognitive complaints predict dementia. Acta Neurologica Scandinavica, 142(6), 585–596. https://doi.org/10.1111/ane.13326

Goldman, J. G., Holden, S. K., Litvan, I., McKeith, I., Stebbins, G. T., & Taylor, J.-P. (2018). Evolution of diagnostic criteria and assessments for parkinson’s disease mild cognitive impairment. Movement Disorders, 33(4), 503–510. https://doi.org/10.1002/mds.27323

Goud, K. Y., Moonla, C., Mishra, R. K., Yu, C., Narayan, R., Litvan, I., & Wang, J. (2019). Wearable electrochemical microneedle sensor for continuous monitoring of levodopa: Toward parkinson management. ACS Sensors, 4(8), 2196–2204. https://doi.org/10.1021/acssensors.9b01127

Guella, I., Evans, D. M., Szu-Tu, C., Nosova, E., Bortnick, S. F., Goldman, J. G., Dalrymple-Alford, J. C., Geurtsen, G. J., Litvan, I., Ross, O. A., Middleton, L. T., Parkkinen, L., & Farrer, M. J. (2016). Α-synuclein genetic variability: A biomarker for dementia in parkinson disease. Annals of Neurology, 79(6), 991–999. https://doi.org/10.1002/ana.24664

Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C., & Postuma, R. B. (2019). Update of the MDS research criteria for Prodromal Parkinson’s disease. Movement Disorders, 34(10), 1464–1470. https://doi.org/10.1002/mds.27802

Hoogland, J., Boel, J. A., de Bie, R. M. A., Geskus, R. B., Schmand, B. A., Dalrymple-Alford, J. C., Marras, C., Adler, C. H., Goldman, J. G., Tröster, A. I., Burn, D. J., Litvan, I., & Geurtsen, G. J. (2017). Mild cognitive impairment as a risk factor for parkinson’s disease dementia. Movement Disorders, 32(7), 1056–1065. https://doi.org/10.1002/mds.27002

Jellinger, K. A. (2015). Neuropathobiology of non-motor symptoms in Parkinson disease. Journal of Neural Transmission, 122(10), 1429–1440. https://doi.org/10.1007/s00702-015-1405-5

Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams-Gray, C. H., Aarsland, D., Kulisevsky, J., Rodriguez-Oroz, M. C., Burn, D. J., Barker, R. A., & Emre, M. (2012). Diagnostic Criteria for Mild Cognitive Impairment in Parkinson’s Disease: Movement Disorder Society Task Force Guidelines. Movement Disorders, 27(3), 349–356. https://doi.org/10.1002/mds.24893

Moreno, G. M., Gandhi, R., Lessig, S. L., Wright, B., Litvan, I., & Nahab, F. B. (2018). Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. Neurology, 91(17), 797–799. https://doi.org/10.1212/wnl.0000000000006396

Parmar, M., Grealish, S., & Henchcliffe, C. (2020). The future of stem cell therapies for Parkinson disease. Nature Reviews Neuroscience, 21(2), 103–115. https://doi.org/10.1038/s41583-019-0257-7

Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., Siderowf, A., Trojanowski, J. Q., & Weintraub, D. (2015). Longitudinal Study of normal cognition in parkinson disease. Neurology, 85(15), 1276–1282. https://doi.org/10.1212/wnl.0000000000002001

Pirogovsky-Turk, E., Moore, R. C., Filoteo, J. V., Litvan, I., Song, D. D., Lessig, S. L., & Schiehser, D. M. (2017). Neuropsychiatric predictors of cognitive decline in parkinson disease: A longitudinal study. The American Journal of Geriatric Psychiatry, 25(3), 279–289. https://doi.org/10.1016/j.jagp.2016.10.004

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for parkinson’s disease. Movement Disorders, 30(12), 1591–1601. https://doi.org/10.1002/mds.26424

Postuma, R. B., Poewe, W., Litvan, I., Lewis, S., Lang, A. E., Halliday, G., Goetz, C. G., Chan, P., Slow, E., Seppi, K., Schaffer, E., Rios-Romenets, S., Mi, T., Maetzler, C., Li, Y., Heim, B., Bledsoe, I. O., & Berg, D. (2018). Validation of the MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 33(10), 1601–1608. https://doi.org/10.1002/mds.27362

Rizek, P., Kumar, N., & Jog, M. S. (2016). An update on the diagnosis and treatment of Parkinson disease. Canadian Medical Association Journal, 188(16), 1157–1165. https://doi.org/10.1503/cmaj.151179

Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (n.d.). Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysi. Neurology, 86, 566–576.

Simon, D. K., Tanner, C. M., & Brundin, P. (2020). Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clinics in Geriatric Medicine, 36(1), 1–12. https://doi.org/10.1016/j.cger.2019.08.002

Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022). Inflammation and immune dysfunction in parkinson disease. Nature Reviews Immunology, 22(11), 657–673. https://doi.org/10.1038/s41577-022-00684-6

Thenganatt, M. A., & Jankovic, J. (2014). Parkinson Disease Subtypes. JAMA Neurology, 71(4), 499. https://doi.org/10.1001/jamaneurol.2013.6233

Weintraub, D., Caspell‐Garcia, C., Simuni, T., Cho, H. R., Coffey, C. S., Aarsland, D., Alcalay, R. N., Barrett, M. J., Chahine, L. M., Eberling, J., Espay, A. J., Hamilton, J., Hawkins, K. A., Leverenz, J., Litvan, I., Richard, I., Rosenthal, L. S., Siderowf, A., & York, M. (2020). Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 7(4), 449–461. https://doi.org/10.1002/acn3.51022

Weintraub, D., Simuni, T., Caspell-Garcia, C., Coffey, C., Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., Eberling, J., Espay, A. J., Foster, E. D., Leverenz, J. B., Litvan, I., Richard, I., Troyer, M. D., & Hawkins, K. A. (2015). Cognitive Performance and Neuropsychiatric Symptoms in Early, Untreated Parkinson’s Disease. Movement Disorders, 30(7), 919–927. https://doi.org/10.1002/mds.26170